Lava Therapeutics Nv Reports Results For The Quarter Ended In March: Earnings Summary

LAVA Therapeutics NV

18/05/2022 14:31

* LAVA Therapeutics NV  LVTX.OQ  reported a quarterly
adjusted
loss of 41 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 81 cents per share.
    * Revenue rose 8.6% to €1.00 million from a year ago; 
analysts
expected €509.00 thousand. 
    * LAVA Therapeutics NV's reported EPS for the quarter was a
loss
of 41 cents​.
    * The mean earnings estimate of analysts had fallen by
about 42%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * LAVA Therapeutics NV shares had fallen by 18.6% this
quarter and
lost 34.9% so far this year.
    * The company reported a quarterly loss of €10.56 million.
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $23.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 18 at 01:30 p.m.  ​All
figures in euros unless otherwise stated